Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Idiopathic Aplastic Anemia in Children and Adults: Diagnosis, Treatments, and Management - A Review

Author(s): Fatmah S. Alqahtany*

Volume 21, Issue 13, 2020

Page: [1282 - 1288] Pages: 7

DOI: 10.2174/1389201021666191210141426

Price: $65

Abstract

Aplastic Anemia (AA) is also known as idiopathic aplastic anemia (IAA) and the production of new blood cells ceases in AA, which leads to an abnormal hematological syndrome such as pancytopenia and suppression of hypo-cellular bone marrow. The pathophysiology of AA in most cases is immune-mediated and is stimulated by type 1 cytotoxic T cells. Reliable early diagnostic tests of IAA are not yet available, therefore most of the cases are identified in advanced stages. Recently, abnormal immune response and hematopoietic cell deficiencies are defined genetically, such as in target cells of telomere repair gene mutations and by the dysregulation of T-cell activation pathways. Importantly, anti-thymocyte globulins and cyclosporine-associated immunosuppression are successful treatments for restoring blood cell production in most of the cases, however, clonal hematologic diseases remain challenging. In the current review, we have discussed the common practices in the treatment, pathophysiology, diagnosis, and management of AA.

Keywords: Aplastic anemia, immunosuppression, leukemia, hematologic diseases, pathophysiology, T-cell activation.

« Previous Next »
Graphical Abstract

[1]
Cuglievan, B.; DePombo, A.; De Angulo, G. Aplastic anemia: The correct nomenclature matters. Haematologica, 2016, 101(9)e391
[http://dx.doi.org/10.3324/haematol.2016.146522] [PMID: 27582572]
[2]
Peslak, S.A.; Olson, T.; Babushok, D.V. Diagnosis and treatment of aplastic anemia. Curr. Treat. Options Oncol., 2017, 18(12), 70.
[http://dx.doi.org/10.1007/s11864-017-0511-z] [PMID: 29143887]
[3]
Jianhui, W.; Lu, Z.; Sufeng, Y.; Haidong, W.; Guoli, W.; Juxiang, Y. Differential diagnosis model of hypocellular myelodysplastic syndrome and aplastic anemia based on the medical big data platform. Complexity, 2018.4824350
[http://dx.doi.org/10.1155/2018/4824350]
[4]
Keohane, E.M. Acquired aplastic anemia. Clin. Lab. Sci., 2004, 17(3), 165-171.
[PMID: 15314891]
[5]
Tischkowitz, M.D.; Hodgson, S.V.J. Fanconi anaemia. J. Med. Genet., 2003, 40(1), 1-10.
[http://dx.doi.org/10.1136/jmg.40.1.1] [PMID: 12525534]
[6]
Kevin, E.B.; John, T.I.; John Barrett, A.; Cynthia, E.D. Kepatitis- associated aplastic anemia. N. Engl. J. Med., 1997, 3361059-3361064.
[7]
Guinan, E.C. Diagnosis and management of aplastic anemia. Hematology (Am. Soc. Hematol. Educ. Program), 2011, 2011, 76-81.
[http://dx.doi.org/10.1182/asheducation-2011.1.76] [PMID: 22160015]
[8]
Chrezenmeier, H.; Bacigalupo, A., Eds.; Aplastic Anemia -Pathophysiology and Treatment; Cambridge University Press, 2000.
[9]
Passweg, J.R.; Marsh, J.C. Aplastic anemia: First-line treatment by immunosuppression and sibling marrow transplantation. Hematology (Am. Soc. Hematol. Educ. Program), 2010, 2010, 36-42.
[http://dx.doi.org/10.1182/asheducation-2010.1.36] [PMID: 21239768]
[10]
Shallis, R.M.; Chokr, N.; Stahl, M.; Pine, A.B.; Zeidan, A.M. Immunosuppressive therapy in myelodysplastic syndromes: A borrowed therapy in search of the right place. Expert Rev. Hematol., 2018, 11(9), 715-726.
[http://dx.doi.org/10.1080/17474086.2018.1503049] [PMID: 30024293]
[11]
Sun, Y.Q.; Chang, Y.J.; Huang, X.J. Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Rev. Hematol., 2018, 11(4), 273-284.
[http://dx.doi.org/10.1080/17474086.2018.1447379] [PMID: 29493370]
[12]
Jang, J.H.; Kim, J.Y.; Mun, Y.C.; Bang, S.M.; Lim, Y.J.; Shin, D.Y.; Choi, Y.B.; Yhim, H.Y.; Lee, J.W.; Kook, H. Management of immune thrombocytopenia: Korean experts recommendation in 2017. Blood Res., 2017, 52(4), 254-263.
[http://dx.doi.org/10.5045/br.2017.52.4.254] [PMID: 29333401]
[13]
Prakash, G.; Yanamandra, U.; Khadwal, A.; Varma, N.; Varma, S.; Malhotra, P. Role of arsenic trioxide in the management of aplastic anemia. Indian J. Hematol. Blood Transfus., 2017, 33(4), 534-536.
[http://dx.doi.org/10.1007/s12288-017-0795-y] [PMID: 29075064]
[14]
Dufour, C. How I manage patients with Fanconi anaemia. Br. J. Haematol., 2017, 178(1), 32-47.
[http://dx.doi.org/10.1111/bjh.14615] [PMID: 28474441]
[15]
Boddu, P.C.; Kadia, T.M. Updates on the pathophysiology and treatment of aplastic anemia: A comprehensive review. Expert Rev. Hematol., 2017, 10(5), 433-448.
[http://dx.doi.org/10.1080/17474086.2017.1313700] [PMID: 28452257]
[16]
Dolberg, O.J.; Levy, Y. Idiopathic aplastic anemia: Diagnosis and classification. Autoimmun. Rev., 2014, 13(4-5), 569-573.
[http://dx.doi.org/10.1016/j.autrev.2014.01.014] [PMID: 24424170]
[17]
Hartung, H.D.; Olson, T.S.; Bessler, M. Acquired aplastic anemia in children. Pediatr. Clin. North Am., 2013, 60(6), 1311-1336.
[http://dx.doi.org/10.1016/j.pcl.2013.08.011] [PMID: 24237973]
[18]
Williams, D.A.; Bennett, C.; Bertuch, A.; Bessler, M.; Coates, T.; Corey, S.; Dror, Y.; Huang, J.; Lipton, J.; Olson, T.S.; Reiss, U.M.; Rogers, Z.R.; Sieff, C.; Vlachos, A.; Walkovich, K.; Wang, W.; Shimamura, A. Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): An initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatr. Blood Cancer, 2014, 61(5), 869-874.
[http://dx.doi.org/10.1002/pbc.24875] [PMID: 24285674]
[19]
Dufour, C.; Svahn, J.; Bacigalupo, A.; Longoni, D.; Varotto, S.; Iori, A.P.; Bagnasco, F.; Locasciulli, A.; Menna, G.; Ramenghi, U.; Lanciotti, M. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica, 2005, 90(8), 1027-1031.
[PMID: 16079101]
[20]
Kurre, P.; Johnson, F.L.; Deeg, H.J. Diagnosis and treatment of children with aplastic anemia. Pediatr. Blood Cancer, 2005, 45(6), 770-780.
[http://dx.doi.org/10.1002/pbc.20322] [PMID: 15706582]
[21]
Guinan, E.C. Aplastic anemia: management of pediatric patients. Hematology (Am. Soc. Hematol. Educ. Program), 2005, 104, 104-109.
[http://dx.doi.org/10.1182/asheducation-2005.1.104] [PMID: 16304366]
[22]
Marsh, J. Making therapeutic decisions in adults with aplastic anemia. Hematology (Am. Soc. Hematol. Educ. Program), 2006, 1, 78-85.
[http://dx.doi.org/10.1182/asheducation-2006.1.78] [PMID: 17124044]
[23]
DeZern, A.E.; Guinan, E.C. Aplastic anemia in adolescents and young adults. Acta Haematol., 2014, 132(3-4), 331-339.
[http://dx.doi.org/10.1159/000360209] [PMID: 25228559]
[24]
Nissen-Druey, C. Pathophysiology of aplastic anaemia. Baillieres Clin. Haematol., 1989, 2(1), 37-49.
[http://dx.doi.org/10.1016/S0950-3536(89)80006-X] [PMID: 2645963]
[25]
Young, N.S.; Calado, R.T.; Scheinberg, P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood, 2006, 108(8), 2509-2519.
[http://dx.doi.org/10.1182/blood-2006-03-010777] [PMID: 16778145]
[26]
Kobayashi, H.; Kitano, K.; Ishida, F.; Saito, H.; Miyabayashi, H.; Yonezawa, T.; Inada, H.; Suzuki, A.; Furuta, S. Aplastic anemia and idiopathic thrombocytopenic purpura with antibody to platelet glycoprotein IIb/IIIa following resection of malignant thymoma. Acta Haematol., 1993, 90(1), 42-45.
[http://dx.doi.org/10.1159/000204372] [PMID: 8237273]
[27]
Wada, H.; Minamikawa, K.; Ohiwa, M.; Kaneko, T.; Mori, Y.; Tamaki, S.; Takagi, M.; Kageyama, S.; Katayama, N.; Minami, N. Elevated plasma interleukin-6 in patient with idiopathic thrombocytopenic purpura. Rinsho Ketsueki, 1991, 32(7), 773-776.
[PMID: 1920840]
[28]
Katoh, O.; Kimura, A.; Fujimura, K.; Kuramoto, A. Progression activity for platelet-derived growth factor in plasma of patients with idiopathic thrombocytopenic purpura and aplastic anemia. Nippon Ketsueki Gakkai Zasshi, 1989, 52(1), 113-117.
[PMID: 2741644]
[29]
Uzuka, Y.; Miyamori, A.; Oka, M.; Yamagata, S. Long-term corticosteroid therapy of idiopathic aplastic anemia. Tohoku J. Exp. Med., 1976, 118(Suppl.), 207-216.
[http://dx.doi.org/10.1620/tjem.118.Suppl_207] [PMID: 964026]
[30]
Kordasti, S.; Costantini, B.; Seidl, T.; Perez Abellan, P.; Martinez Llordella, M.; McLornan, D.; Diggins, K.E.; Kulasekararaj, A.; Benfatto, C.; Feng, X.; Smith, A.; Mian, S.A.; Melchiotti, R.; de Rinaldis, E.; Ellis, R.; Petrov, N.; Povoleri, G.A.; Chung, S.S.; Thomas, N.S.; Farzaneh, F.; Irish, J.M.; Heck, S.; Young, N.S.; Marsh, J.C.; Mufti, G.J. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood, 2016, 128(9), 1193-1205.
[http://dx.doi.org/10.1182/blood-2016-03-703702] [PMID: 27281795]
[31]
Robak, T.; Krykowski, E.; Warzocha, K. Treatment of chemotherapy-induced or idiopathic bone marrow aplasia with granulocyte colony-stimulating factor (G-CSF). Arch. Immunol. Ther. Exp. (Warsz.), 1994, 42(5-6), 433-438.
[PMID: 8572903]
[32]
Camitta, B.M.; Thomas, E.D.; Nathan, D.G.; Santos, G.; Gordon-Smith, E.C.; Gale, R.P.; Rappeport, J.M.; Storb, R. Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood, 1976, 48(1), 63-70.
[http://dx.doi.org/10.1182/blood.V48.1.63.63] [PMID: 779871]
[33]
Bacigalupo, A.; Hows, J.; Gluckman, E.; Nissen, C.; Marsh, J.; Van Lint, M.T.; Congiu, M.; De Planque, M.M.; Ernst, P.; McCann, S.; Ragavashar, A.; Frickhofen, N.; Wursch, A.; Marmont, A.M.; Cordon-Smith, E.C. Bone Marrow Transplantation (BMT) versus immunosuppression for the treatment of Severe Aplastic Anaemia (SAA): A report of the EBMT SAA working party. Br. J. Haematol., 1988, 70(2), 177-182.
[http://dx.doi.org/10.1111/j.1365-2141.1988.tb02460.x] [PMID: 3056497]
[34]
Rovó, A.; Tichelli, A.; Dufour, C. Diagnosis of acquired aplastic anemia. Bone Marrow Transplant., 2013, 48(2), 162-167.
[http://dx.doi.org/10.1038/bmt.2012.230] [PMID: 23165495]
[35]
Danielson, D.A.; Douglas, S.W., III; Herzog, P.; Jick, H.; Porter, J.B. Drug-induced blood disorders. JAMA, 1984, 252(23), 3257-3260.
[http://dx.doi.org/10.1001/jama.1984.03350230017024] [PMID: 6151006]
[36]
Bhatnagar, N.; Samarasinghe, S. Diagnosis and management of childhood aplastic anaemia. Paediatr. Child Health, 2015, 25, 343-349.
[http://dx.doi.org/10.1016/j.paed.2015.04.001]
[37]
Chou, D. Henry’s clinical diagnosis and management by laboratory methods. JAMA, 2000, 297, 1827-1833.
[http://dx.doi.org/10.1001/jama.297.16.1829]
[38]
Shimamura, A. Clinical approach to marrow failure. Hematology (Am. Soc. Hematol. Educ. Program), 2009, 329-337.
[http://dx.doi.org/10.1182/asheducation-2009.1.329] [PMID: 20008218]
[39]
Calado, R.T.; Cooper, J.N.; Padilla-Nash, H.M.; Sloand, E.M.; Wu, C.O.; Scheinberg, P.; Ried, T.; Young, N.S. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia, 2012, 26(4), 700-707.
[http://dx.doi.org/10.1038/leu.2011.272] [PMID: 22005790]
[40]
Scheinberg, P.; Cooper, J.N.; Sloand, E.M.; Wu, C.O.; Calado, R.T.; Young, N.S. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA, 2010, 304(12), 1358-1364.
[http://dx.doi.org/10.1001/jama.2010.1376] [PMID: 20858879]
[41]
Kim, T.O.; Despotovic, J.; Lambert, M.P. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv., 2018, 2(4), 454-461.
[http://dx.doi.org/10.1182/bloodadvances.2017010660] [PMID: 29487060]
[42]
Gargiulo, L.; Papaioannou, M.; Sica, M.; Talini, G.; Chaidos, A.; Richichi, B.; Nikolaev, A.V.; Nativi, C.; Layton, M.; de la Fuente, J.; Roberts, I.; Luzzatto, L.; Notaro, R.; Karadimitris, A. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood, 2013, 121(14), 2753-2761.
[http://dx.doi.org/10.1182/blood-2012-11-469353] [PMID: 23372165]
[43]
Taniguchi, Y.; Frickhofen, N.; Raghavachar, A.; Digel, W.; Heimpel, H. Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur. J. Haematol., 1990, 44(4), 244-251.
[http://dx.doi.org/10.1111/j.1600-0609.1990.tb00387.x] [PMID: 2188853]
[44]
Sayyed, A.H.; Aleem, A.; Al-Katari, M.S.; Algahtani, F.; Aljerian, K.; Aleem, T.A.; Alsaleh, K. acute lymphoblastic leukemia presenting with liver infiltration and severe lactic acidosis. Am. J. Case Rep., 2018, 19, 453-457.
[http://dx.doi.org/10.12659/AJCR.907383] [PMID: 29662049]
[45]
Alqahtany, B.; AlQahtani, F.S.A.; Khojah, O.; Almaeen, A.; Aamer, A. optimal response to imatinib therapy in a case of chronic myeloid leukemia with a concurrent loss of distal 22q. J. Appl. Hematol., 2017, 8, 152-155.
[http://dx.doi.org/10.4103/joah.joah_34_17]
[46]
Masilamani, V.; Devanesan, S.; AlSalhi, M.S.; AlQahtani, F.S.A.; Farhat, K. Fluorescence spectral detection of acute lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML): A novel photodiagnosis strategy. A photodiagnosis approach; Photodiagn Photodyn, 2019, p. 101634.
[http://dx.doi.org/10.1016/j.pdpdt.2019.101634]] [PMID: 31870897]
[47]
Aamer, A.; Al Wusibai, F.; AlSaleh, K.; AlQahtani, F.S.A.; Zafar, I.; Naeem, C.; Al-Momen, A.K. Multiple brain hemorrhages on presentation in a patient with accelerated phase chronic myeloid leukemia and subsequent CNS blast crisis despite systemic complete molecular response: Possible role of CNS bleed in leukemia proliferation. Blood, 2015, 126, 5153.
[http://dx.doi.org/10.1182/blood.V126.23.5153.5153]
[48]
Farhan, S.; AlQahtani, F.S.A.; Al-Anazi, K.A. Chronic myeloid leukemia presenting with priapism. J. Leuk., 2015, 3, 1.
[49]
Davies, J.K.; Guinan, E.C. An update on the management of severe idiopathic aplastic anaemia in children. Br. J. Haematol., 2007, 136(4), 549-564.
[http://dx.doi.org/10.1111/j.1365-2141.2006.06461.x] [PMID: 17214739]
[50]
Bacigalupo, A.; Bruno, B.; Saracco, P.; Di Bona, E.; Locasciulli, A.; Locatelli, F.; Gabbas, A.; Dufour, C.; Arcese, W.; Testi, G.; Broccia, G.; Carotenuto, M.; Coser, P.; Barbui, T.; Leoni, P.; Ferster, A. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: An update of the GITMO/EBMT study on 100 patients. Blood, 2000, 95(6), 1931-1934.
[http://dx.doi.org/10.1182/blood.V95.6.1931] [PMID: 10706857]
[51]
Frickhofen, N.; Heimpel, H.; Kaltwasser, J.P.; Schrezenmeier, H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood, 2003, 101(4), 1236-1242.
[http://dx.doi.org/10.1182/blood-2002-04-1134] [PMID: 12393680]
[52]
Saracco, P.; Quarello, P.; Iori, A.P.; Zecca, M.; Longoni, D.; Svahn, J.; Varotto, S.; Del Vecchio, G.C.; Dufour, C.; Ramenghi, U.; Bacigalupo, A.; Locasciulli, A. Cyclosporin A response and dependence in children with acquired aplastic anaemia: A multicentre retrospective study with long-term observation follow-up. Br. J. Haematol., 2008, 140(2), 197-205.
[http://dx.doi.org/10.1111/j.1365-2141.2007.06903.x] [PMID: 18173756]
[53]
Samarasinghe, S.; Webb, D.K.H. How I manage aplastic anaemia in children. Br. J. Haematol., 2012, 157(1), 26-40.
[http://dx.doi.org/10.1111/j.1365-2141.2012.09058.x] [PMID: 22348483]
[54]
Rosenfeld, S.J.; Kimball, J.; Vining, D.; Young, N.S. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood, 1995, 85(11), 3058-3065.
[http://dx.doi.org/10.1182/blood.V85.11.3058.bloodjournal85113058] [PMID: 7756640]
[55]
Suzuki, K.; Muramatsu, H.; Okuno, Y.; Narita, A.; Hama, A.; Takahashi, Y.; Yoshida, M.; Horikoshi, Y.; Watanabe, K.; Kudo, K.; Kojima, S. Immunosuppressive therapy for patients with Down syndrome and idiopathic aplastic anemia. Int. J. Hematol., 2016, 104(1), 130-133.
[http://dx.doi.org/10.1007/s12185-016-1997-z] [PMID: 27107757]
[56]
Georges, G.E.; Storb, R. Hematopoietic stem cell transplantation for acquired aplastic anemia. Curr. Opin. Hematol., 2016, 23(6), 495-500.
[http://dx.doi.org/10.1097/MOH.0000000000000281] [PMID: 27607445]
[57]
Hernández-Rivera, E.G. Hematopoietic stem-cell transplantation in aplastic anemia. Rev. Invest. Clin., 2005, 57(2), 298-304.
[PMID: 16524071]
[58]
Marsh, J.C.W.; Ball, S.E.; Cavenagh, J.; Darbyshire, P.; Dokal, I.; Gordon-Smith, E.C.; Keidan, J.; Laurie, A.; Martin, A.; Mercieca, J.; Killick, S.B.; Stewart, R.; Yin, J.A.; Yin, A. Guidelines for the diagnosis and management of aplastic anaemia. Br. J. Haematol., 2009, 147(1), 43-70.
[http://dx.doi.org/10.1111/j.1365-2141.2009.07842.x] [PMID: 19673883]
[59]
Zeng, Y.; Wang, S.; Wang, J.; Liu, L.; Su, Y.; Lu, Z.; Zhang, X.; Zhang, Y.; Zhong, J.F.; Peng, L.; Liu, Q.; Lu, Y.; Gao, L.; Zhang, X. Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China. Sci. Rep., 2018, 8(1), 2479.
[http://dx.doi.org/10.1038/s41598-018-20853-9] [PMID: 29410500]
[60]
Sun, Q.; Wu, B.; Zhu, Z.; Sun, C.; Xu, J.; Long, H.; Huang, Y.; Xu, J.; Song, C. Allogeneic hematopoietic stem cell transplant for severe aplastic anemia: Current state and future directions. Curr. Stem Cell Res. Ther., 2018, 13(5), 350-355.
[http://dx.doi.org/10.2174/1574888X12666170227151226] [PMID: 28245775]
[61]
Ashish, O.G.; Steven, L.S.; Jignesh, D.D. hematopoeitic stem cell transplant in aplastic anemia: Is it time to revise the treatment alogirthm. Blood, 2016, 128, 2395.
[http://dx.doi.org/10.1182/blood.V128.22.2395.2395]
[62]
Dezern, A.E.; Brodsky, R.A. Clinical management of aplastic anemia. Expert Rev. Hematol., 2011, 4(2), 221-230.
[http://dx.doi.org/10.1586/ehm.11.11] [PMID: 21495931]
[63]
Scheinberg, P. Current management of severe acquired aplastic anemia. Einstein (Sao Paulo), 2011, 9(2), 229-235.
[http://dx.doi.org/10.1590/s1679-45082011rw2156] [PMID: 26760822]
[64]
AlQahtani, F.S.A.; Farhat, K.; Alshebly, M.M. Comparison of flow cytometric and immunohistochemical immunophenotyping data for diagnosis of B-cell neoplasms and classic Hodgkin’s lymphoma. J. Nat. Sci. Biol. Med., 2019, 22, 35-40.
[65]
Marsh, J.C.; Kulasekararaj, A.G. Management of the refractory aplastic anemia patient: What are the options? Blood, 2013, 122(22), 3561-3567.
[http://dx.doi.org/10.1182/blood-2013-05-498279] [PMID: 24052548]
[66]
DiBona, E.; Rodeghiero, F. Bruno, B.; Gabbas, A.; Foa, P.; Locasciulli, A; Rosanelli, C.; Camba, L.; Saracco, P.; Lippi, A.; Iori, A.P.; Porta, F.; De-Rossi, V.; Comotti, B.; Iacopino, P.; Dufour, C.; Bacigalupo, A. Rabbit Antithymocyte Globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br. J. Haematol., 1999, 107, 330-334.
[http://dx.doi.org/ https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2141.1999.01693.x] [PMID: 10583220]

Rights & Permissions Print Cite
Article Metrics
37
2
© 2024 Bentham Science Publishers | Privacy Policy